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Abstract 
Background: Cancer stem cells (CSCs), which have been isolated from various malignancies, were closely correlated 
with the occurrence, progression, metastasis and recurrence of the malignant cancer. Little is known about the tumor 
stem-like cells (TSLCs) isolated from benign tumors. Here we want to explore the global expression profile of RNA of 
tumor stem-like cells isolated from MMQ rat prolactinoma cells.
Methods: In this study, total RNA was extracted from MMQ cells and MMQ tumor stem-like cells. RNA expression 
profiles were determined by Agilent Rat 8 × 60 K Microarray. Then we used the qRT-PCR to test the result of Microar-
ray, and found VEGFA had a distinct pattern of expression in MMQ tumor stem-like cells. Then WB and ELISA were 
used to confirm the VEGFA protein level of tumor sphere cultured from both MMQ cell and human prolactinoma cell. 
Finally, CCK-8 was used to evaluate the reaction of MMQ tumor stem-like cells to small interfering RNAs intervention 
and bevacizumab treatment.
Result: The results of Microarray showed that 566 known RNA were over-expressed and 532 known RNA were low-
expressed in the MMQ tumor stem-like cells. These genes were mainly involved in 15 different signaling pathways. 
In pathway in cancer and cell cycle, Bcl2, VEGFA, PTEN, Jun, Fos, APC2 were up-regulated and Ccna2, Cdc25a, Mcm3, 
Mcm6, Ccnb2, Mcm5, Cdk1, Gadd45a, Myc were down-regulated in the MMQ tumor stem-like cells. The expression 
of VEGFA were high in tumor spheres cultured from both MMQ cell and human prolactinomas. Down-regulation of 
VEGFA by small interfering RNAs partially decreased cell viability of MMQ tumor stem-like cells in vitro. Bevacizumab 
partially suppressed the proliferation of MMQ tumor stem-like cells.
Conclusions: Our findings characterize the pattern of RNA expression of tumor stem-like cells isolated from MMQ 
cells. VEGFA may act as a potential therapeutic target for tumor stem-like cells of prolactinomas.
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Background
Prolactinomas are the most common subtype of pituitary 
adenomas with the proportion ranging from 40 to 66%, 
and occur with the population prevalence of 6–10 per 
100,000 per year [1–3]. Since the mid–1980s, dopamine 
agonists (DA) have become the first-line therapy for the 
patients with prolactinomas [2, 4, 5]. However, it is not 
known how prolactinomas develop and tumor recur-
rence after withdrawal of DA treatment.
Cancer stem cells (CSCs) are defined as the unique 
subpopulation in the tumor, which possess the ability to 
initiate tumor growth and sustain self-renewal as well 
as metastatic potential [6, 7]. The further research dis-
covered that cancer stem cells, which had been isolated 
from leucocythemia and other various malignancies, 
were closely correlated with the occurrence, progres-
sion, metastasis and recurrence of the malignant cancer 
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[8–10]. However, little is known about the tumor stem-
like cells (TSLCs) isolated from benign tumors. Xu [11] 
had proved for first time that tumor stem-like cells can be 
isolated from pituitary adenoma. Recently, Chen [12] and 
Mertens [13] had further demonstrated that the tumor 
stem-like cells were existed and identificated in pitui-
tary adenoma. However, the global expression profile of 
RNA in tumor stem-like cells (TSLCs) isolated from pro-
lactinoma kept unknown. Medical treatment is the first 
choice for prolactinoma [2, 4, 5], which results in limited 
tumor specimen source, moreover, there are small num-
ber of cells available from human prolactinoma postsur-
gical samples for in vitro experiments. Human pituitary 
adenomas cells grow very slowly in vitro [13], then it is 
difficult to get enough tumor cells to evaluate the molec-
ular characteristic of TSLCs from human prolactinoma. 
MMQ rat prolactinoma cells are traditionally used as a 
substitutes for human prolactin-secreting pituitary ade-
noma cells in laboratory experiments, mainly because 
stably express prolactin (PRL) and have similar biological 
characteristics [14]. Therefore, research on characteriz-
ing RNAs expression of MMQ tumor stem-like cells will 
help to lay the foundation for human prolactinoma.
In this study, total RNA was extracted from three clas-
sical cultured MMQ cells and three MMQ tumor stem-
like cells cultured in serum-free suspension medium 
containing growth factor. Then, their RNA expression 
profiles were determined by Agilent Rat 8 × 60 K Micro-
array. We validated these differentially expressed RNA by 
qRT-PCR and analyzed their potential function. Further-
more, the expression of VEGFA which over-expressed in 
the MMQ tumor stem-like cells was detected in tumor 
spheres isolated from human prolactinomas. Finally, 
we evaluated the cell viability after down-regulation of 
VEGFA by small interfering RNAs and the reaction to 
bevacizumab in MMQ tumor stem-like cells.
Methods
MMQ cell culture and reagents
MMQ rat prolactinoma cell line was used in this study, 
which was purchased from the Cell Bank of the Shang-
hai Branch of Chinese Academy of Sciences, and cultured 
in F12 medium (Gibco, Grand Island, NY, USA) supple-
mented with 2.5% fetal bovine serum (FBS, Gibco), 15% 
horse serum (Gibco) and 100 U/ml penicillin/streptomy-
cin (Gibco). Cells were maintained in humidified atmos-
phere with 37 °C and 5% CO2.
MMQ tumor stem‑like cell culture and reagents
To obtain MMQ tumor stem-like cells, as described in 
our previous report [15], in brief, MMQ cells were cul-
tured in DMEM/F12 medium (Gibco) supplemented 
with B27 (1×, Gibco), EGF (20 ng/ml, Preprotech, Rocky 
Hill, NJ, USA), bFGF (20 ng/ml, Preprotech) and 100 U/
ml penicillin/streptomycin (Gibco). After been cultured 
for 2–3 weeks, MMQ tumor spheres can grow and form 
in serum-free suspension medium. Then, the MMQ 
tumor spheres were identified by immunofluorescence 
examination of stem cell markers and transplantation 
assay (see Additional file 1: Figure S1). Finally, the MMQ 
tumor spheres were resuspended and incubated with 
Rabbit anti-CD133 (1:50, MyBioSource, USA) for 30 min 
at 4  °C. After washing with PBS, cells were incubated 
with FITC-conjugated Donkey anti-Rabbit IgG (1:50, 
Santa Cruz, USA) for 30 min at 4 °C. Subsequently, FACS 
Calibur Flow Cytometer (BD Biosciences) was used to 
isolate and collect the CD133 positive tumor stem-like 
cells from the MMQ tumor spheres.
Patients and tissue samples
Tumor specimens were obtained from pituitary prol-
actinomas resected via the transsphenoidal approaches 
in Department of Neurosurgery, First Affiliated Hospi-
tal of Wenzhou Medical University from March 2012 
to December 2015. Research was approved by Clinical 
Medicine ethics Committee of First Affiliated Hospital of 
Wenzhou Medical University (permission: 2012–2013). 
Five pituitary adenomas samples (n  =  5; 3 men and 2 
women) were classified as prolactinomas according to 
the 2004 edition of the World Health Organization clas-
sification of pituitary tumors [16], which were ranged 
in age from 27 to 54  years. All had increased prolactin 
serum levels from 112.1 to >2000  ng/ml and the tumor 
volumes varied from 365 to 7800  mm3. Tumor tissues 
were immersed in DMEM medium (Gibco) for cell cul-
ture development.
Human prolactinoma cell culture
Tissue samples were disaggregated with scalpel, washed 
in DMEM and fractured further by pipetting. Tumor 
cells were released from the tissues by enzymatic treat-
ment with trypsase (Gibco) and grown in DMEM with 
15% Fetal Bovine Serum (Gibco) until reaching conflu-
ency. Then tumor cells were collected and cultured in 
serum-free suspension medium which similar to MMQ 
tumor stem-like cells. Tumor spheres can grow and form 
in serum-free suspension medium after 2 to 3  weeks. 
Then, the human prolactinoma spheres were identified 
by immunofluorescence examination of stem cell mark-
ers (see Additional file 2: Figure S2).
RNA extraction and evaluation
MMQ cells and CD133 positive tumor stem-like cells 
were homogenized in TRIzol reagent and total RNA was 
isolated according to the manufacturer’s protocol (Invit-
rogen, CA). The concentration and purity of total RNA 
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were determined by an ultraviolet spectrophotometer at 
260 and 280 nm.
Microarrays and gene expression analysis
An Agilent gene expression array (KangChen Bio-tech 
Inc.) was used to investigate the global expression pro-
file of MMQ tumor stem-like cells; the array represented 
more than 41,000 transcripts (http://www.kangchen.
com.cn). The microarray datasets were normalized in 
Gene Spring GX using the Agilent FE one-color scenario 
(mainly quantile normalization). Differentially expressed 
genes were identified through fold-change screening (fold 
change ≥2.0). The gene ontology (GO) biological process 
and Kyoto encyclopedia of genes and genomes (KEGG) 
pathway enrichment analysis were performed using the 
Database for Annotation, Visualization and Integrated 
Discovery 6.7, (DAVID; http://david.abcc.ncifcrf.gov/) 
and were ranked by P values [17, 18].
Verification of the RNA expression by qRT‑PCR
Quantitative real-time RT-PCR (qRT-PCR) was used to 
verify RNA expression identified by Agilent Rat 8 × 60 K 
Microarray. The primers for the identified RNA were 
designed using Premier 5.0. Mixtures of 1  µg of total 
RNAs, 50 nM reverse primer, 5 units of M-MLV reverse 
transcriptase (Toyobo), 2 units of the RNAase inhibitor 
(Toyobo, Osaka, Japan) and 0.5  µM dNTP were incu-
bated for 30  min at 16  °C, 30  min at 42  °C and 15  min 
at 70 °C. The reaction mixes were used as the templates 
for qRT-PCR using SYBR® Green Real-time PCR Master 
Mix-Plus (Toyobo, Osaka, Japan) on the Applied Biosys-
tems 7500 detection system. The PCR mixture including 
1  µl RT product of total RNA, 10  µl SYBR-Green Real-
time PCR Master Mix-plus, 2 µl plus solution, 2 µl each 
specific forward and reverse primers, and 3  µl DEPC 
water was made up the final volume to 20 µl. The reaction 
was performed at 95 °C for 2 min, followed by 40 cycles 
at 95 °C for 15 s and 60 °C for 1 min. Each sample was ran 
in triplicate and actin was used as internal control. Melt-
ing curves were used for verifying the specificity of each 
PCR reaction. The cycle threshold (Ct) was the mean 
value of three Ct values. The relative expression level of 
RNA was analyzed by the 2−∆∆Ct method.



































Actin (Human -Forward): 5′-gggacctgactgactacctc-3′;
Actin (Human -Reverse): 5′-tcatactcctgcttgctgat-3′
Western Blot
Proteins were separated on a 12% SDS-PAGE gel and 
transferred to a nitrocellulose membrane (Bio-Rad, Her-
cules, USA). The membrane was blocked with 5% non-
fat milk and incubated with Rabbit anti-VEGFA mAb 
(epitomics) or rabbit anti-Actin mAb (cell signaling). 
After being washed extensively, a goat anti-rabbit sec-
ondary antibody (Cell Signaling Technology, Massachu-
setts, USA) was added to the system. The proteins were 
detected using ECL reagents (Pierce).
Enzyme‑linked immunosorbent assays (ELISAs)
The level of VEGFA of supernatant from culture medium 
was measured using a commercially available ELISA 
kit, according to the manufacturer’s instructions (Excell 
biology, Shanghai, China). The minimal detectable con-
centration was 4 pg/mL for VEGFA. The inter-assay and 
intra-assay coefficients of variation were less than 10%.
Gene silencing assay
MMQ tumor stem-like cells and MMQ cells grown in 
6-well plates to  ~50% confluency were serum-starved 
overnight and transfected with 100 pmol Silencer® Select 
Negative Control #1 siRNA (Cat. No. 4390843, Ambion, 
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USA) and Silencer® Select Pre-Designed VEGFA siRNA 
(Cat. No. 4390771; ID: s236285, Ambion, USA) for 24 h 
using Lipofectamine™ 2000 (Invitrogen) according to the 
manufacturer’s instructions. After an additional 8 h incu-
bation (serum-free medium), samples were collected at 
indicated times for further study.
Cell proliferation assay
Cell proliferation was measured using the CCK-8 assay 
kit (Dojindo, Japan). 10,000 cells, treated with bevaci-
zumab (Roche, 4 mg/μl) or DMSO for 72 h, were plated 
into each well of a 96-well plate. On the day of harvest, 
10 μl CCK-8 was added to 90 μl of culture medium. The 
cells were subsequently incubated for 4  h at 37  °C and 
the optical density was measured at 450 nm. Three inde-
pendent experiments were performed.
Statistical analysis
Data were described as mean ± SEM. The T test statis-
tic was applied to evaluate the difference between MMQ 
cells with tumor stem-like cells. P < 0.05 was considered 
as a significant difference. The calculations were per-
formed with the software SPSS 17.0.
Results
Overview of gene expression array
Microarray systems were broadly used to investigate 
gene expression patterns and functional classification 
in stem cell [19]. In this paper, to evaluate the gene dif-
ferences between MMQ cells and tumor stem-like cells, 
we extracted RNA from three classical cultured MMQ 
cells and three MMQ tumor stem-like cells cultured in 
serum-free suspension medium containing growth fac-
tor, and hybridized in Agilent Rat 8  ×  60  K microar-
rays. The resulting data were analyzed by the GABRIEL 
(Genetic Analysis by Rules Incorporating Expert Logic) 
system, a knowledge based system of computer algo-
rithms. As shown in Fig.  1a, the distributive differ-
ences of all detection gene probe (excluding controlled 
probe and flagged probe) in Agilent Rat 8  ×  60  K 
microarrays tended to normal distribution, which was 
accurate and practical value. The expression levels of 
RNAs in the two libraries were normalized. The vol-
cano plots of RNAs in classical MMQ cells and MMQ 
tumor stem-like cells was shown in Fig.  1b, the inclu-
sion criteria of alternative gene: the expression of the 
gene was changed more than 2.0 folds and the P value 
was less than 0.05. After trimming sequences with con-
taminants, the results of Microarray showed that 566 
known RNA were over-expressed (the blue spots on 
the right), and 532 known RNA were specially low-
expressed in the MMQ tumor stem-like cells (the blue 
spots on the left).
Biological processes analysis of the gene expression 
profiles
GO analysis is a functional analysis associating differen-
tially expressed genes with GO categories. The GO cat-
egories are derived from Gene Ontology (http://www.
geneontology.org), which comprises three structured 
networks of defined terms to describe gene product 
attributes. This functional analysis was used to predict 
significant differences between MMQ cells and tumor 
stem-like cells. As shown in Table 1, pathway in cancer, 
MAPK signaling pathway, regulation of actin cytoskel-
eton, focal adhesion, tight junction, cell cycle, leukocyte 
transendothelial migration, oocyte meiosis, TGF-beta 
signaling pathway, gluconeogenesis, P53 signaling path-
way, glutathione metabolism, valine leucine and iso-
leucine degradation, fatty acid metabolism, butanoate 
metabolism were shown to be significantly regulated with 
more than 500 genes differential expression in two group 
(Fig. 1c; P value < 0.01).
Differential expression of RNAs between two groups 
in pathway in cancer and cell cycle
Earlier studies [20] had shown that cancer stem cells 
played a key role in neurogenic tumor regeneration, 
metastasis and recurrence. Cancer stem cells was resist-
ant to conventional chemo- and radio-therapy, which 
was a important factor in drug resistance and recurrence 
[21–23]. Given that conventional therapies preferentially 
targeted cycling cells, quiescence was thought to render 
cancer stem cells resistant to such treatment [24, 25]. 
Based on the above, further study in pathway in cancer 
and cell cycle between MMQ cells and tumor stem-like 
cells were taken into consideration. According to the 
clustering analysis of three times independent microarray 
experiments (Fig.  1d). We rearranged the gene involved 
in these two cell signal pathway, stably changed more 
than 3.0-folds were chosen to in-depth study. As shown 
in Additional file  3: Table S1, 82 candidate genes were 
selected.
Evaluation of gene expression changes by qRT‑PCR
To verify the Microarray analysis results, ten classical 
cultured MMQ cells and ten MMQ tumor stem-like cells 
were used to perform qRT-PCR for the identified RNAs. 
15 differential expressed genes existed steady difference, 
Bcl2, VEGFA, PTEN, Jun, Fos, APC2 were up-regulated 
and Ccna2, Cdc25a, Mcm3, Mcm6, Ccnb2, Mcm5, Cdk1, 
Gadd45a, Myc were down-regulated in MMQ tumor 
stem-like cells group (P < 0.05, Fig. 1e).
Gene ontology (GO) category and pathway analysis
The cell signaling pathway of those 15 RNAs were pre-
dicted by KEGG and Database of gene ontology (GO). 
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In pathway in cancer, we found that Bcl2, VEGFA, 
PTEN, Jun, Fos, APC2 gene expression were up-regu-
lated and the expression of Myc was down-regulated in 
the MMQ TSLCs. In the pathway in cell cycle, we found 
that the expression of Ccna2, Cdc25a, Mcm3, Mcm6, 
Ccnb2, Mcm5, Cdk1, Gadd45a were down-regulated in 
the MMQ tumor stem-like cells. (see Additional file 4: 
Figure S3, Additional file 5: Figure S4)
Table 1 Biological processes analysis of the gene expression profiles
Geneset name Genes in geneset Description Genes in overlap (k) k/K P value
Pathway in cancer 317 Genes annotated by the KEGG 
rno05200:pathways in cancer
25 0.07886 0.0159
MAPK signaling pathway 266 Genes annotated by the KEGG 
rno04010:MAPK signaling pathway
21 0.07895 0.0281
Regulation of action cytoskeleton 209 Genes annotated by the KEGG 
rno04810:regulation of action 
cytoskeleton
19 0.09091 0.0106
Focal adhesion 195 Genes annotated by the KEGG 
rno04510:focal adhesion
20 0.10256 0.0023
Tight junction 130 Genes annotated by the KEGG 
rno04530:tight junction
17 0.13077 0.0004
Cell cycle 126 Genes annotated by the KEGG 
rno04110:cell cycle
18 0.14286 8.7916E−05




Oocyt meiosis 111 Genes annotated by the KEGG 
rno04114:oocyt meiosis
12 0.10811 0.0163
TGF-beta signaling pathway 86 Genes annotated by the KEGG 
rno04350:TGF-beta signaling pathway
11 0.12791 0.0075
Glycolysis/gluconeogenesis 84 Genes annotated by the KEGG 
rno00010:glycolysis/gluconeogenesis
10 0.11905 0.018
p53 signaling pathway 66 Genes annotated by the KEGG 
rno04115:p53 signaling pathway
11 0.16667 0.001
Glutathione metabolism 50 Genes annotated by the KEGG 
rno00480:glutathione metabolism
7 0.14 0.0306
Valine leucine and isoleucine degrada-
tion
46 Genes annotated by the KEGG 
rno00280:valine leucine and isoleu-
cine degradation
7 0.15217 0.0211
Fatty acid metabolism 42 Genes annotated by the KEGG 
rno00071:fatty acid metabolism
6 0.14286 0.0481
Butanoate metabolism 33 Genes annotated by the KEGG 
rno00650:butanoate metabolism
7 0.21212 0.0042
(See figure on previous page.) 
Fig. 1 Overview of gene expression array. a Normal distribution of RNAs in classical MMQ cells and MMQ TSLCs. The Log2 absciss are presented the 
differences existing between the 2 group. The vertical axis showed the number of probe. In general, the figure become approximately normally 
distribution, which showed the up-regulated RNA should be roughly the same as the down-regulated RNA. b Volcano Plots of RNAs in classical 
MMQ cells and MMQ TSLCs. The Log2 absciss are presented the differences existing between the 2 group. The vertical axis showed the P value, 
which represented the significance of the difference. The red line mean the P = 0.05. The inclusion criteria of alternative gene: the expression of the 
gene was changed more than 2.0 folds (the green line) and the P value was less than 0.05 (the red line). Microarray showed that 566 known RNA 
were over-expressed and 532 known RNA were low-expressed in the MMQ TSLCs. c Biological processes analysis of the gene expression profiles. 15 
pathway were shown to be significantly regulated with more than 500 genes differential expression in two group. d The cluster analysis of classical 
MMQ cells and MMQ TSLCs. Further study in pathway in cancer and cell cycle between MMQ cells and TSLCs were taken into consideration. Accord-
ing to the clustering analysis of three times independent microarray experiments, 82 candidate genes were selected. E. To verify the 82 candidate 
genes, MMQ cells and MMQ TSLCs were used to perform qRT-PCR for the identified RNAs. 15 differential expressed genes existed steady difference. 
*P < 0.05, **P < 0.01. TSLC tumor stem-like cell
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VEGFA expression was up‑regulated in MMQ tumor 
stem‑like cells
As previously reported [27], VEGFA was confirmed to 
associate with promoting cancer stemness, and played 
an important role in the neovascularization of TSLCs. To 
further investigate the exact effect of VEGFA in MMQ 
tumor stem-like cells. As shown in Fig. 2a, VEGFA mRNA 
expression in MMQ tumor stem-like cells were increased 
273.2% compared with MMQ cells (P < 0.01). Morever, we 
found the level of VEGFA in culture medium supernatant 
of MMQ tumor sphere cells was 77.9% higher than that 
in MMQ cells (Fig. 2b, P < 0.01). The protein expression 
of VEGFA increased 102.3% in MMQ tumor sphere cells 
compared with MMQ cells (Fig. 2c, P < 0.01).
VEGFA expression was up‑regulated in human 
prolactinoma tumor sphere cells
In next set of experiments, we wanted to further vali-
date the expression of VEGFA in human prolactinoma. 
Tumor cells from 5 human prolactinomas were col-
lected and cultured in serum-free suspension medium 
for 2–3 weeks, which were similar to MMQ tumor stem-
like cells, human prolactinoma tumor spheres could grow 
and form (see Additional file 2: Figure S2). Then we found 
that VEGFA mRNA increased 55.5% in human prolacti-
noma tumor spheres, and the expression of VEGFA pro-
tein was also significantly increased compared with the 
original generation cells (Fig. 2d, e).
VEGFA silencing suppressed the growth of MMQ tumor 
stem‑like cells in vitro
To address the efficacy of VEGFA on MMQ tumor stem-
like cells, we down-regulated the expression of VEGFA 
in MMQ cells and MMQ tumor stem-like cells by small 
interfering RNAs. As shown in Fig. 3a, b, MMQ cells and 
tumor stem-like cells transfected with VEGFA siRNA 
showed efficient silencing of VEGFA expression, as evalu-
aed by real-time RT-PCR (Fig. 3a) and immunoblot analy-
sis (Fig.  3b). VEGFA mRNA expression decreased 43.7 
and 33.9% in MMQ tumor stem-like cells and MMQ cells 
by siRNA silencing compared with siControl transfected 
cells, respectively. The protein expression of VEGFA 
decreased 32.4 and 26.6% in tumor stem-like cells and 
MMQ cells by siRNA silencing, respectively. In cell viabil-
ity assay, tumor stem-like cells showed reduction of cell 
viability by VEGFA silencing compared with siControl 
Fig. 2 VEGFA expression was up-regulated in MMQ tumor stem-like cells and human prolactinoma tumor sphere cells. a VEGFA mRNA expression 
in MMQ TSLCs significantly increased compared with that in MMQ cells. b The VEGFA level of culture medium supernatant from MMQ TSLCs was 
higher than that from MMQ cells. c The protein expression of VEGFA significantly increased in MMQ TSLCs compared with MMQ cells evaluated by 
WB. d Human prolactinoma tumor spheres cultured in serum-free suspension medium had higher VEGFA mRNA, evaluated by qRT-PCR, com-
pared with the original generation cells. e The expression of VEGFA protein of human prolactinoma tumor spheres was also significantly increased 
compared with that of the original generation cells. TSLC tumor stem-like cell, T human prolactinoma tumor spheres, O original generation cells of 
human prolactinoma. **P < 0.01
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transfected cells (Fig. 3c). At 96 h after transfected siRNA, 
cell viability reduced 16.5%. The cell viability has no differ-
ence between transfected with VEGFA siRNA and trans-
fected with SiControl in MMQ cells (data not shown). 
These finding showed that VEGFA may be required for 
the growth of tumor stem-like cells in vitro.
Bevacizumab could inhibit the proliferation of MMQ tumor 
stem‑like cells in vitro
Bevacizumab, prevented solid tumor from growing 
by suppressing the production of VEGF, was the most 
commonly used anti-angiogenesis chemotherapy. The 
viability of MMQ tumor stem-like cells treated with bev-
acizumab decreased 19.7% compared with the DMSO 
group at 72 h. However, there were no significant differ-
ence in MMQ between bevacizumab group and DMSO 
group (Fig. 3d). These findings demonstrated that beva-
cizumab partially inhibited the proliferation of MMQ 
tumor stem-like cells.
Discussion
An increasing body of evidence has indicated that can-
cer stem cells are the root of tumor metastasis and 
recurrence [26]. Cancer stem cells do not only reserve 
the characteristics of stem cells, but also have their own 
nature. The research of the tumor stem cells will give a 
new therapeutic approach for targeting tumor [27]. How-
ever, no study has been reported which investigated the 
RNAs expression profile for tumor stem-like cells iso-
lated from pituitary prolactinoma.
The present study reports, to our knowledge for the 
first time, the RNA expression profile in MMQ tumor 
stem-like cells in comparison with MMQ cells. Agilent 
Rat 8  ×  60  K Microarray was performed to screen the 
differential RNAs. The results of Microarray showed that 
566 known RNA were over-expressed and 532 known 
RNA were low-expressed in the MMQ tumor stem-like 
cells. These genes were mainly involved in 15 differ-
ent signaling pathways. After validated by qRT-PCR, 
we found that 15 RNAs were differentially expressed 
between MMQ tumor stem-like cells and MMQ cells 
in the pathway in cancer and cell cycle. Bcl2, VEGFA, 
PTEN, Jun, Fos, APC2 were up-regulated and Ccna2, 
Cdc25a, Mcm3, Mcm6, Ccnb2, Mcm5, Cdk1, Gadd45a, 
Myc were down-regulated in MMQ tumor stem-like cells 
group.
The theory of cancer stem cell proposed that the tumor 
tissue had its own cancer stem cells in it and regarded 
Fig. 3 The growth-suppressive effect of VEGFA silencing and bevacizumab on MMQ tumor stem-like cells in vitro. a, b The effect of VEGFA knock-
down via siRNA silencing in TSLC and MMQ cells. The cells were transfected with siControl or siVEGFA for 72 h and subjected to quantitative PCR 
and immunoblot analysis of VEGFA expression. c VEGFA knockdown via siRNA silencing inhibited the proliferation of TSLC. The cells were transfected 
with siControl or siVEGFA for 24–96 h and subjected to cell proliferation assay by CCK-8. d 10,000 MMQ TSLC, treated with bevacizumab (4 mg/μl) 
or DMSO for 72 h, were plated into each well of a 96-well plate and subjected to cell proliferation assay by CCK-8. The viability of MMQ TSLC treated 
with bevacizumab decreased compared with the negative DMSO group. TSLC: tumor stem-like cell. *P < 0.05, **P < 0.01, ***P < 0.001
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cancer stem cell as the key to regeneration, metasta-
sis and recurrence [20]. If its stem cells were eradicated, 
the rest of a tumour might die off [28]. In order to clarify 
the differences of gene expression in tumour formation, 
we put research emphasis on the pathway in cancer. We 
found that Bcl2, VEGFA, PTEN, Jun, Fos, APC2 gene 
expression were up-regulated and the expression of Myc 
was down-regulated in the MMQ TSLCs. These differen-
tially expressed genes were mainly involved in cell apop-
tosis and differentiation. Studies show that APC was an 
E3 ligase enzyme [29], which might combine with Bcl2 
to protected TSLCs from apoptosis process by increas-
ing the stability of mitochondrial outer membrane, halt-
ing the intrinsic apoptotic pathways [30] and possessing 
the ability to infinite differentiation. Jun and Fos were 
overexpression in MMQ tumor stem-like cells, they 
were the important component of AP-1 transcriptional 
activating complex [31], Which might play a key role in 
the differentiation of cancer stem cells. AP-1 could pro-
mote dopaminergic neuronal differentiation by combin-
ing with PTEN [32]. The expression alteration of these 
gene describe above suggested that MMQ tumor stem-
like cells owned more efficient anti-apoptosis ability and 
were more tolerated than MMQ cells to the changes of 
cultured condition in vitro, such as medication treatment 
and nutrient scarcity. Their self-renewal and differentia-
tion are under strict control, if the conditions are suita-
ble, tumor stem-like cells could immediately differentiate 
into the daughter cells and form tumors rapidly. These 
results are consistent with previous studies [6, 7, 25, 33].
Earlier studies had shown that TSLCs maintained in 
a non-proliferative state (referred to as quiescence, dor-
mancy, or G0 phase) and entered the cell cycle infre-
quently [33, 34]. Given that conventional therapies 
preferentially targeted cycling cells, quiescence was 
thought to render TSLCs resistant to chemo- and radio-
therapy [24, 25]. In the pathway in cell cycle, we found 
that the expression of Ccna2, Cdc25a, Mcm3, Mcm6, 
Ccnb2, Mcm5, Cdk1, Gadd45a were down-regulated 
in the MMQ tumor stem-like cells. The expression of 
Ccna2, Ccnb2, and Cdk1 were low, which could reduce 
G1/S-phase arrest [35] and the transition from G2 to 
M phase [36], furthermore enhanced the ability of anti-
apoptosis of tumor stem cells [37]. Mcm3, Mcm5, Mcm6 
proteins had been identified as important participants of 
DNA replication [38] and Cdc25a [39] and Gadd45a [40] 
was essential for DNA repair. The low expression of the 
gene might contribute to the delay in cell cycle and the 
decrease of DNA repair, the damaged or mutated DNA 
might be a key role in tumor stem cells infinite prolifera-
tion. Our results might help to explain the mechanism of 
tumor stem-like cells maintained in a non-proliferative 
state.
One of the most interesting observations of the current 
study was that VEGFA had a distinct pattern of expres-
sion in MMQ tumor stem-like cells and was further vali-
dated in tumor spheres of human prolactinoma.
VEGFA was a central regulator of angiogenesis [41, 42]. 
VEGFA could created a perivascular niche for TSLCs 
by stimulating angiogenesis in a paracrine manner, and 
directly stimulated cancer stemness and renewal [43].
The pituitary contains abundant VEGFA [44], and 
VEGFA participated in the formation of the vascular 
network of a new pituitary tumor [45, 46], and increased 
tumoral VEGFA expression was observed during the 
development of estrogen-induced prolactinoma in rats 
[47]. These data indicated that VEGFA might contrib-
ute to adequate temporal vascular supply. Furthermore, 
VEGFA expression was related to invasion of pitui-
tary adenoma [48]. The expression of VEGFA obviously 
increased in pituitary adenoma with extrasellar growth 
than that in intrasellar ones, suggesting VEGFA could 
be markers for poor outcome after tumor resection [49]. 
Previous studies [50, 51] revealed that VEGFA protein 
expression was high in the dopamine agonist resistant 
prolactinomas. Furthermore, the patients with tumor 
recurrence showed a significant rise in serum concen-
trations of VEGFA. The antiangiogenic treatments were 
effective in inhibiting the growth of primary dopamine 
resistant prolactinomas as well as the transplanted ade-
nomas [52]. In our study, both expression and secretion 
of VEGFA increased obviously in tumor stem-like cells of 
prolactinomas. Our results, integrating with the reports 
mentioned above, indicated that VEGFA secreted by 
tumor stem-like cells might play a key role in the occur-
rence and progression of prolactinoma and act as a 
potential therapeutic target.
There are several limitations in this study. Firstly, the 
high expression of VEGFA in MMQ tumor stem-like 
cells is tested in vitro, the in vivo environment is so much 
more complicated than in cell lines. Secondly, the regula-
tion mechanisms of VEGFA in the tumor stem-like cells 
is not clear. Here, a further experiment is needed to con-
firm how the VEGF is involved in human prolactinomas 
formation and progression in  vivo. This may help us to 
have a much better understanding of the mechanism for 
the beneficial effect of tumor stem-like cells on prolacti-
nomas formation.
Conclusion
In conclusion, our study characterize the pattern of RNA 
expression of MMQ stem-like cells. This finding may 
provide potential targets for development of TSLC-based 
therapies and lay the foundation for the further study in 
RNA-involved mechanism of MMQ tumor stem-like 
cells in the future.
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